Prospective study of the correlation between expression of Corticotropin-Releasing Hormone and prognosis of pancreatic tumor, and QOL survey

Prospective study of the correlation between expression of Corticotropin-Releasing Hormone and prognosis of pancreatic tumor, and QOL survey - Prospective study of the correlation between expression of CRH and prognosis of pancreatic tumor, and QOL survey

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009592

Enrollment

200

Registered

2012-12-20

Start date

2012-12-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Possibly resectable of Pancreatic tumor 2. No previous therapy 3. ECOG PS of 0 or 1 4. tolerable function of bone marrow, liver and kidney.. 5. Possible oral intake. 6. written informed consent 7. over 20 years old

Exclusion criteria

Exclusion criteria: 1. Pulmonary fibrosis or interstitial pneumonitis 2. Patients expectd R2 resection 3. Patients with synclonous double cancer 4. Active infection 5. HBs Ag positive 6. Patients requiring the administration of flucytosine, phenytoin or warfarin potassium 7. Patients who are pregnant or possibly pregnant. 8.The patient judged to be unsuitable by attending doctor

Design outcomes

Primary

Measure	Time frame
evaluate the correlation of disease free survival and CRH expression	—

Secondary

Measure	Time frame
evaluate the correlation of overall Survival, progression-Free Survival, QOL	—

Countries

Japan

Contacts

Public ContactKei Nakagawa

Tohoku University Graduate School of Medicine Integrated Surgery and Oncolog

kein_h11@surg1.med.tohoku.ac.jp022-717-7205

Outcome results